Skip to main content
ADPT
NASDAQ Life Sciences

Adaptive Biotechnologies Q1 Revenue Jumps 35% to $70.9M, Raises Full-Year MRD Guidance

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$16
Mkt Cap
$2.122B
52W Low
$8.375
52W High
$20.76
52W Position info
91% above low
Off High info
23% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ADPT sits 91% above its 52-week low of $8.375.

Summary

Adaptive Biotechnologies reported robust first-quarter 2026 financial results, with total revenue increasing 35% year-over-year to $70.9 million and its key MRD revenue segment surging 53% to $67.1 million. The company also significantly narrowed its adjusted EBITDA loss to $2.5 million, demonstrating improved operational efficiency. This strong performance is further underscored by a 41% increase in clonoSEQ test volumes, driving the growth in the MRD business, which now constitutes 95% of total revenue. Crucially, management raised its full-year MRD revenue guidance to $260–$270 million, signaling strong commercial momentum and a positive outlook for its core business. This positive earnings report and upward revision of guidance are material catalysts for the stock, indicating a stronger-than-expected trajectory. Traders will be watching for continued execution on the raised guidance and further progress towards sustained profitability.

At the time of this announcement, ADPT was trading at $16.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $8.38 to $20.76. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Nov 04, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.48
Real-time Price: $28.64 info
Change: +$0.155 (+0.54%) info
Market Cap: $4.654B info
ADPT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $28.80
Real-time Price: $28.64 info
Change: -$0.1649 (-0.57%) info
Market Cap: $4.654B info
ADPT
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $27.98
Real-time Price: $28.64 info
Change: +$0.655 (+2%) info
Market Cap: $4.654B info
ADPT
Aug 19, 2026, 8:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $28.64 info
Change: +$2.84 (+11%) info
Market Cap: $4.654B info
ADPT
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.66
Real-time Price: $28.64 info
Change: +$3.97 (+16%) info
Market Cap: $4.654B info